Clearmind Medicine Inc. Retains Edge Communications Group for Investor Relations, Announces Grant of Stock Options
Toronto, Ontario – (Newsfile Corp. – July 2, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clear mind“or the”Company“), a psychedelic medicine biotechnology company focused on the discovery and development of novel therapies derived from psychedelics to address widespread and underserved health problems, today announced that it has retained Edge Growth Holdings Corporation (“Edge Communications Group” or “Edge“) for strategic investor relations and capital markets communications services (the”Agreement“).
Clearmind CEO Gadi Levin said: “We follow Edge closely and have always been impressed with their innovation in investor relations. We believe our company story will resonate particularly well with their target population, and we are delighted to begin a professional relationship that we believe will benefit our shareholders.. “
Edge is a team of capital markets communications professionals with a special focus on engaging Millennial and Gen Z investors. Edge will provide Clearmind with a full spectrum communications strategy that combines traditional investor communications with new era platforms such as Instagram, TikTok, Discord and Reddit.
Under the agreement, Clearmind will pay Edge Communications Group a monthly fee of C $ 10,000 for ongoing strategic communications services. In addition, Kevan Matheson will receive 100,000 stock options with an exercise price of $ 0.84 which will vest after 4 months and have a term of two years. The Agreement is for an initial term of four months. At the time of this announcement, neither Edge Communications Group nor any of its officers have any interest, directly or indirectly, in Clearmind or its securities.
In addition, the Company wishes to announce that in accordance with the terms of the Company’s stock option plan, it has granted a total of 800,000 options (the “Options“), with an exercise price of $ 0.84, of which 600,000 options were issued to the directors and officers and the remainder, 200,000 options, to the consultants of the Company. The options will vest in twelve (12) installments. equal quarterly over a 36-month period, with one-twelfth of the Options vested at the end of each quarter with the first vesting on October 1, 2021.
About Clearmind Medicine Inc.
Clearmind is a biotechnology and psychedelic medicine company focused on the discovery and development of novel therapies derived from psychedelics to address widespread and underserved health issues, including alcohol use disorders. Its main objective is to research and develop compounds derived from psychedelics and to attempt to market them as regulated drugs, foods or supplements.
The Company’s intellectual portfolio currently consists of two patent families, one for binge behavior regulators and the other for an alcoholic beverage substitute. Within these two families, the Company holds two US patents, one European patent and authorized applications in China and India and pending divisional applications in Europe and the United States relating to regulators of excessive behavior; and a European patent and pending applications in the United States, China and India relating to the family of alcoholic beverage substitutes.
For more information, please contact:
For other requests
This press release may contain forward-looking statements and information based on current expectations. These statements should not be interpreted as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those implied by such statements. These statements include the submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and the raising of sufficient funding to carry out the Company’s business strategy. There is no certainty that any of these events will occur. Although these statements are based on reasonable assumptions of management, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing in early stage companies inherently involves a high degree of risk and investing in securities of the Company will be considered highly speculative.
This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of securities in any province where such an offer, solicitation or sale would be illegal. The securities issued or to be issued under the private placement have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States upon no registration or applicable exemption from registration requirements.
Neither the Canadian Securities Exchange nor its regulatory services provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Do not distribute to US news agencies or broadcast in the United States.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/89288